Welcome to our dedicated page for Bone Biologics news (Ticker: BBLG), a resource for investors and traders seeking the latest updates and insights on Bone Biologics stock.
Bone Biologics Corporation (NASDAQ: BBLG, BBLGW) is a biotechnology company developing orthobiologic products for spine fusion markets, with a focus on bone regeneration using NELL-1-based technology. This news page brings together company announcements and disclosures that highlight its scientific, clinical, operational and capital markets activities.
Readers can review updates on Bone Biologics’ lead product candidate NB1, which the company describes as a combination of recombinant human NELL-1 (rhNELL-1) and demineralized bone matrix for use as a bone graft in spinal fusion procedures. News items include descriptions of the company’s first-in-human clinical study in degenerative disc disease, where NB1 is being evaluated for safety and preliminary effectiveness in transforaminal lumbar interbody fusion.
Coverage also includes operational milestones such as extensions of rhNELL-1 shelf life from earlier 12- and 18-month validations to a reported 24-month validated shelf life, as well as formulation improvements intended to support scaled manufacturing. Intellectual property developments, including the filing of a U.S. patent application for compositions of rhNELL-1 polypeptide and uses in treating bone conditions, are documented in press releases.
Investors and observers can find information on public offerings of common stock and warrants, reverse stock split actions, and communications about Nasdaq listing compliance. The company’s participation in investor conferences and stockholder letters discussing clinical progress, manufacturing readiness, and outlook for NB1 are also reflected in the news flow. This page serves as a centralized source for Bone Biologics’ historical news, helping users follow its orthobiologic development program and related corporate events over time.
Bone Biologics (NASDAQ: BBLG) summarized 2025 operational, scientific, and corporate milestones and provided a 2026 outlook. Key 2025 achievements include extending validated shelf life of its rhNELL-1 protein to 24 months, completing a registered public offering raising $5.0 million in Q2 2025, filing a U.S. patent application for its rhNELL-1 bone regeneration technology, and regaining Nasdaq minimum bid price compliance in June 2025. For 2026 the company plans to advance its NB1 clinical program with expected completion of patient enrollment in its first-in-human trial, continue manufacturing and regulatory readiness efforts, pursue additional patent protection, and maintain capital discipline.
Bone Biologics (NASDAQ: BBLG) announced a validated extension of the shelf life for its rhNELL-1 product to 24 months, supported by ongoing stability data and following prior validated 12- and 18-month milestones. The company said this achievement aligns with previously communicated forecasts.
The 24-month shelf life is expected to improve manufacturing efficiency, inventory management, supply-chain flexibility and clinical and commercial readiness as rhNELL-1 advances through development, and the company framed the milestone as supportive of disciplined capital deployment and long-term shareholder value creation.
Bone Biologics (NASDAQ: BBLG) CEO Jeffrey Frelick provided a comprehensive update on the company's progress in developing NB1, a novel bone fusion treatment combining NELL-1 protein with demineralized bone matrix. The company is conducting a first-in-human pilot study in Australia, evaluating NB1's safety and effectiveness in patients with degenerative disc disease undergoing spinal fusion.
Key developments include achieving an extended shelf life of 18 months for the protein, filing a U.S. patent application, and completing a $5 million public offering. The company expects to complete trial enrollment by year-end 2025, with current cash runway extending into Q2 2026. The clinical trial is evaluating two NB1 concentrations against autograft control in up to 30 subjects.
Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8-10, 2025 at the Lotte New York Palace Hotel.
The company's President and CEO, Jeffrey Frelick, will be available for one-on-one meetings with institutional investors and industry professionals, who can register to attend either virtually or in person.
Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, has successfully closed its previously announced $5.0 million public offering. The offering consisted of 1,250,000 shares of common stock (or equivalents) and two series of warrants at a public offering price of $4.00 per share.
The offering includes Series D warrants with a 5-year term and Series E short-term warrants with an 18-month term, both with an exercise price of $4.00 per share. If fully exercised, these warrants could provide additional gross proceeds of $10.0 million. H.C. Wainwright & Co. served as the exclusive placement agent for the offering.
The company plans to use the net proceeds to fund clinical trials, maintain and extend its patent portfolio, and for working capital and general corporate purposes.
Bone Biologics (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, has announced the pricing of a $5.0 million public offering. The offering consists of 1,250,000 shares of common stock (or equivalents) at $4.00 per share, along with Series D and Series E warrants.
The offering includes Series D warrants with a 5-year term and Series E short-term warrants with an 18-month term, both with an exercise price of $4.00 per share. If fully exercised, the warrants could provide additional gross proceeds of $10.0 million. The company plans to use the proceeds for clinical trials, patent portfolio maintenance, and working capital.
Bone Biologics (NASDAQ: BBLG) has filed a patent application with the USPTO for its novel NELL-1 protein technology. The application covers compositions of rhNELL-1 polypeptide and its applications in treating bone conditions.
The patent filing represents a significant milestone for the company's intellectual property portfolio and supports their clinical development program in spine fusion treatments.
Bone Biologics (NASDAQ:BBLG), a developer of orthobiologic products for spine fusion markets, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation from Nasdaq that it has met the listing requirement of maintaining a closing bid price of $1.00 or more for at least 10 consecutive trading days, achieving this milestone on June 24, 2025.
This development resolves the non-compliance notice issued on April 7, 2025, and ensures BBLG's continued listing on the Nasdaq Capital Market. The company is now in full compliance with all applicable Nasdaq listing standards.
Bone Biologics (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, has appointed Phillip T. Meikle to its Board of Directors. Mr. Meikle brings over 30 years of commercial experience in the orthopedic and spine industry. He succeeds Don R. Hankey, who retired after seven years of service. The board remains at four directors.
Mr. Meikle was previously the president and CEO of Biosystems of New England, Inc., an orthopedic distribution company he founded in 1992 and sold to Stryker in 2019. He has been a consultant to Stryker Spine for the past five years. His company served as a distributor for Stryker Spine from 2002 to 2019 and for Medtronic Spine from 1992 to 2002.
Jeffrey Frelick, president and CEO of Bone Biologics, expressed enthusiasm about Mr. Meikle's appointment, citing his extensive experience with orthopedic and spine products as particularly valuable as the company develops NB1 for spinal fusion patients.